BEIJING, Sept. 13, 2025 /PRNewswire/ — Amid a century of profound changes, China, standing at a crossroads faced by the world, always fosters certainty, opportunity, and future-oriented growth through its high-quality development.

Chinese President Xi Jinping has noted that “Chinese modernization naturally calls for high-quality development by overcoming economic challenges and making steady progress. Its immutable goal is to deliver a better life to the whole of more than 1.4 billion Chinese people. For the world, this means a broader market and unprecedented cooperation opportunities. It will also instill strong impetus in the global modernization endeavor,” according to the Xinhua News Agency.

In the first half of 2025, as global economic development faced multiple challenges, China achieved an impressive GDP growth rate of 5.3 percent, solidifying its role as a major contributor to global economic growth and becoming a stabilizing anchor for the world.

On July 29, the International Monetary Fund’s World Economic Outlook raised its forecast for China’s 2025 economic growth from 4.0 percent to 4.8 percent, citing China’s stellar economic performance in the first half of the year.

From the China International Import Expo (CIIE) and the China International Fair for Trade in Services to the Belt and Road Initiative (BRI), and from green renewable energy contributor to expanding e-commerce partnerships with 36 countries, China continues to inject positive momentum into a turbulent world.

Supply chain stabilizer

China’s strong supply capability makes it a major player and the cornerstone of global supply chain. In the first eight months of 2025, China’s goods trade grew steadily, with total imports and exports reaching 29.57 trillion yuan ($4.15 trillion), with exports rising 6.9 percent to 17.61 trillion yuan.

Foreign media outlets have noted China’s manufacturing and its export system’s considerable scale and adaptability in navigating trade frictions.

China’s supply chain stability helps back up global material and commodity flows. Despite global disruptions, China meets international demand with high-quality goods supply, becoming a reliable and dynamic part of global trade.

This reliability is based on three major aspects – diverse market scale, comprehensive industrial chain and continuous technological innovation.

China strengthens global trade ties through diversified partnerships. The country’s trade with ASEAN, its top partner, increased by 9.7 percent in the first eight months of this year, while that with BRI partner countries grew by 5.4 percent. This network fosters global flows of goods and deeper cooperation.

With a manufacturing value-added share of about 30 percent globally, China’s complete industrial system enables rapid responses to global market needs.

Recently, an American businessman, also a Canton Fair regular participant, noted, “From the blueprint to providing a sample, Chinese factories would deliver within 72 hours; and from Guangdong Province to US store shelves, it’s about one month.” This illustrates China’s efficiency.

China leads in green, digital, and intelligent technologies, which helps drive overall industrial upgrading in the world. Tailored solutions like solar-powered phones for power-scarce places and durable engines for desert climates assist to transform renewable energy access.

Giant market shared

China’s vast domestic market and its opening-up policy always help create global opportunities.

The CIIE exemplifies China’s commitment to sharing its market with the world. By July 25, with 100 days until the 8th CIIE, more than 40 global corporations had already registered for the 9th session held in Shanghai.

How does the Chinese market offer new opportunities for global economic development?

First, its massive market scale. China, the world’s second-largest consumer and import market, recorded 28.42 trillion yuan in total size in 2024, up 4.8 percent year on year, while total imports reached more than 20 trillion yuan.

Second, its ever-growing consumer base. China’s large middle-income group drives consumption of all kinds of goods and services, from youth trends to the silver economy. Service sectors like tourism and health care, plus digital consumption and blind box trends, fuel growth.

Third, its open policies. Initiatives such as import promotion demonstration zones and recurring events like the CIIE to bring more global goods and services into China. Measures including the 2025 Action Plan for Stabilizing Foreign Investment, the removal of all manufacturing entry restrictions for foreign-funded enterprises, and 155 pilot programs to expand opening-up in services have further enhanced openness. In the first half of 2025, 30,014 new foreign-funded enterprises were set up in China, up by 11.7 percent.

These developments show that China was, is, and will remain an ideal, safe, and promising destination for foreign investment.

Innovative cooperation models

China is offering a new paradigm for global development through providing cooperation solutions and models.

And, China always advocates resolving differences through dialogue.

On July 28-29, China and the US held trade talks in Stockholm, with candid, constructive discussions on trade and macroeconomic policy. On August 12, China and the US decided to extend the suspension of 24 percent reciprocal tariffs for 90 days.

From China-US high-level meeting on economic and trade affairs in Geneva in May, to the first meeting of the China-US economic and trade consultation mechanism in London in June, and to July’s trade talks in Stockholm, the path of resolving economic and trade issues through dialogue and negotiation has become increasingly clear.

And, China prioritizes cooperation over confrontation.

The BRI, as exemplified by China-Central Asia ties, helps promote shared prosperity among the partner economies. In 2025, China and Central Asia signed a permanent friendship treaty, marking a milestone in regional diplomacy. The BRI and Global Development Initiative drive inclusive globalization, benefiting Africa, Europe and beyond.

China’s Global Development Initiative, the Global Security Initiative, the Global Civilization Initiative, and the Global Governance Initiative form a framework for a shared future, addressing global challenges through unity.

China’s actions show it is a proactive force for propelling global development. By advancing high-level opening-up and sharing its market, China offers great opportunities, adding certainty into global growth.

BERLIN, Sept. 12, 2025 /PRNewswire/ — Every September, the world of consumer tech gathers in Berlin for IFA, one of the largest technology trade shows in the world. 2025 marks Antigravity’s first entry onto the scene.

Antigravity’s First-Ever Public Appearance

IFA 2025 marked the public debut of Antigravity A1, the world’s first 8K 360 drone.^[1] Sharing a big booth with Insta360, Antigravity let thousands of visitors experience immersive drone flight firsthand. The combination of A1, the Vision goggles, and Grip controller allowed visitors to immerse themselves in the future of flight.

The response was overwhelming, with visitors expressing excitement over A1’s capabilities, many referring to it as a game changer and industry disruptor. With many looking forward to being able to tell new stories with the unique combination of technologies in A1. Others were excited that they could share memories in new and immersive ways.

Recognition From the Industry

Antigravity A1 received 18 industry awards at IFA 2025, including several Best of IFA titles from leading outlets such as Wired, Tom’s Guide and TechRadar. The recognition highlights A1’s breakthrough combination of 360 capture, intuitive control, and advanced flight technology.

Looking Ahead

Antigravity’s debut comes at a pivotal moment for the drone industry, where innovation has slowed. With the A1, Antigravity is redefining aerial exploration and setting a new standard for immersive flight experiences.

“Antigravity A1 makes high-quality drone footage simple for anyone to capture,” said Jason England of Tom’s Guide.

IFA 2025 is just the beginning. Antigravity will showcase A1 at additional global trade shows in the months ahead, ensuring more people can experience what is already being called one of the most exciting drones in years.

About Antigravity

Antigravity is a consumer drone company reimagining how people experience flight. Incubated by Insta360 in collaboration with third parties, Antigravity develops powerful 360 drones that are immersive, creator-ready, and easy for anyone to fly — whether capturing family moments, weekend adventures, or creative projects.

Antigravity on Social Media

YouTube
Instagram
Facebook
X (formerly Twitter)
TikTok
LinkedIn

^[1]The term world’s first refers to the fact that, as of July 28, 2025, Antigravity has announced the market’s first 8K all-in-one 360 drone. It captures high-quality 360 video directly without the need for an external 360 camera attachment. The drone features a built-in 360 camera, supports real-time data transmission, and allows users to adjust shooting parameters on the fly.

1^st Half revenue grew 452.1% to $32.3 million YoY

IM8 achieved $5.9 million revenue in August 2025, representing a CAGR^[1] of over 3,100%

Prenetics increases FY2025 revenue guidance range of $85 – $100 million

Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily

Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward

HONG KONG, Sept. 12, 2025 /PRNewswire/ — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2025, along with recent business updates.

Danny Yeung, Chief Executive Officer and Co-Founder remarked “This quarter marks a pivotal moment for Prenetics as we demonstrate the successful execution of our strategic vision. The phenomenal growth of IM8, which is on track to achieve an unprecedented $100 million in annual recurring revenue within just our first year of operations, represents a milestone that is virtually unheard of in any industry. With IM8 currently generating $5.9 million in monthly revenue in August, we aim to hit $9 million per month by the end of the year, which would solidify our path to this extraordinary achievement. With such strong growth momentum, we believe we can build IM8 into one of the World’s largest health and wellness brands in the coming years. Beyond the financial metrics, what makes me truly proud is the positive impact IM8 has had on so many people’s health and wellness journeys – with over 8 million servings delivered and more than 300,000 customer orders, we are genuinely making a difference in people’s lives.”

Danny further added “We’ve embraced a new strategic philosophy focused on optimizing both health and wealth – just as IM8 enhances people’s physical well-being, our disciplined Bitcoin treasury strategy is designed to enhance our financial well-being and create long-term value preservation for our shareholders. We are not just building a successful health sciences company; we are building a company that is forward-thinking and resilient. With a strong balance sheet of $90 million in cash and BTC, a clear path to profitability in early 2026, and multiple avenues for growth, we are more confident than ever in our ability to deliver significant and sustainable long-term value to our shareholders.”

Second Quarter 2025 Financial Highlights^[2]

• Revenue of $17.7 million in the second quarter of 2025, an increase of 594.9% as compared to the second quarter of 2024.
• Gross profit of $7.3 million in the second quarter of 2025, an increase of 233.5% as compared to the second quarter of 2024.
• Adjusted EBITDA^[3] loss of $(4.1) million in the second quarter of 2025, a decrease of 8.7% as compared to the first quarter of 2025.
• Loss of $(10.9) million in the second quarter of 2025, an increase of 22.7% as compared to the second quarter of 2024.
• Adjusted current assets^[4] were $90.3 million, including $63.5 million of cash. As of September 10, 2025, the Company held 228.42 Bitcoin^[5] with a value of $26.1 million and remained debt-free.

Second Quarter Business Unit Revenue Breakdown:

• IM8 – $9.8 million (Increase of 70% over Q1)
• Europa – $5.7 million
• CircleDNA – $2.2 million

First Half 2025 Financial Highlights

• Revenue of $32.3 million in the first half 2025, an increase of 452.1% as compared to the first half 2024.
• Gross profit of $13.2 million in the first half 2025, expanded by 166.4% as compared to the first half 2024.
• Adjusted EBITDA loss of $(8.7) million in the first half 2025, an increase of 45.4% as compared to the first half 2024.
• Loss of $(19.8) million in the first half 2025, an increase of 30.2% as compared to the first half 2024.

First Half Business Unit Revenue Breakdown:

• IM8 – $15.5 million
• Europa – $12.0 million
• CircleDNA – $4.8 million

Business Updates and Strategic Initiatives

IM8 Strong Business Momentum:

IM8 Health, a brand 100% wholly owned by Prenetics, has rapidly emerged as one of the fastest-growing supplement brands globally since its launch in December 2024. The brand’s high-profile status with David Beckham as its co-founding partner is further bolstered by its multi-year partnership with Aryna Sabalenka, the World No. 1 tennis player and 2025 US Open champion, who serves as a global ambassador and Prenetics shareholder. The brand’s marketing prowess was demonstrated during the US Open with an AI-powered Aryna Sabalenka video that went viral on Instagram, generating an extraordinary 233 million views. The campaign also featured prominently on the iconic Times Square billboard throughout the US Open and will continue running through the end of September, showcasing IM8’s ability to capture global attention and drive brand awareness at scale.

IM8 has further strengthened its scientific advisory board with the addition of Dr. Darshan Shah, a leading regenerative medicine physician and longevity expert; Dr. Ara Suppiah, a renowned sports medicine specialist and performance optimization physician; and Simon Hill, a prominent nutritionist and plant-based nutrition advocate. Looking ahead, the company is very excited about its new upcoming products, which will be best-in-class from a science perspective, further strengthening IM8’s position as a leader in premium nutrition and longevity solutions.

IM8 has demonstrated exceptional growth, with monthly net revenue surging from $581,000 in December 2024 to $5.9 million in August 2025, representing a compound annual growth rate (CAGR)^[1] of over 3,100%. This remarkable performance is underscored by strong underlying business fundamentals and a highly efficient customer acquisition strategy. In the first half of 2025, IM8 Health achieved a 80%+ new customer subscription rate and an average order value of $110, reflecting strong customer loyalty and high-value transactions. With a gross margin of 52% and a customer acquisition cost of $104 in the first half of 2025, the brand’s unit economics are compelling, further evidenced by an implied LTV/CAC ratio of 4.8x. To date, IM8 has processed more than 300,000 customer orders and delivered more than 8 million servings of its flagship product, IM8 Daily Ultimate Essentials, solidifying its position as a significant player in the crowded health and wellness market.

IM8 Health – Key Performance Indicators (1H 2025 unless otherwise indicated)

Strategic Bitcoin Treasury Initiatives:

Leveraging our strong cash position and robust business fundamentals, we initiated a disciplined treasury reserve program in the second quarter, starting with an initial $20 million purchase of 187.42 BTC at an average price of $106,712 BTC in June 2025. This was followed by our programmatic daily accumulation of Bitcoin as a primary treasury reserve asset, funded directly from our operating cash beginning on August 1, 2025. As of September 10, 2025, the company holds 228.42 BTC on its balance sheet, acquired at an overall average price of approximately $108,131 per BTC. At the current Bitcoin price of $115,105, this position reflects an unrealized gain of approximately $1.6 million, equating to an annualized yield of roughly 30% since the initiation of our program in June 2025.

Looking ahead, we plan to continue our disciplined approach with daily acquisitions of 1 BTC through the remainder of 2025⁶, with expectations to further increase our accumulation rate in 2026 as our cash generation continues to strengthen. Additional purchase will be funded from available cash flows while maintaining prudent operating liquidity. This strategic move reflects our conviction in Bitcoin as a superior store of value and a compelling, non-correlated asset with significant long-term appreciation potential. By systematically converting a portion of our cash flows into Bitcoin, we are not only preserving our capital against inflationary pressures but also positioning Prenetics to capture the asymmetric upside of this emerging asset class. We believe this proactive and forward-thinking treasury management approach will enhance our financial strength and create substantial long-term value for our shareholders.

To further enhance transparency, we have launched a dedicated Bitcoin Treasury Analytics page, which provides real-time updates on our holdings and performance, available at: https://www.prenetics.com/btc 

Business Outlook

Prenetics increases full-year 2025 guidance range of $85 – 100 million in revenue and expects to achieve breakeven by Q1 2026. Our combination of disciplined execution in consumer health, strengthening brand equity at IM8, a flexible capital markets posture, and strong balance sheet positions Prenetics to deliver significant growth.

Breakdown of Full-Year Business Unit Revenue Guidance:

• IM8: $55 – $60 million
• Europa: $20 – $25 million
• CircleDNA: $10 – $15 million

ACT Genomics Divestment

We announced on June 18, 2025 on the divestment of ACT Genomics to Delta Electronics, Inc for a total transaction value of approximately $71.8 million, with a gross proceeds to Prenetics of $46.3 million as settlement. Closing is progressing as planned and is expected in Q4 2025. In line with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, ACT Genomics has been classified as a disposal group held for sale and a discontinued operation. Accordingly, its results are presented separately from continuing operations, and prior-period comparatives have been re-presented for consistency.

About Prenetics

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World’s fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial $20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. To learn more please visit www.prenetics.com and www.IM8health.com. 

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com. 

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including revenue ranges and breakdown timing) reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company’s ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Basis of Presentation

Prior year/ period figures have been re-presented in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, as result of the ACT Genomics divestment, the Group has classified ACT Genomics as held for sale and discontinued operations in June 2025.

Unaudited Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading “Unaudited Non-IFRS Financial Measures”.

Unaudited Non-IFRS Financial Measures

To supplement Prenetics’ consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”), the Company is providing non-IFRS measure, adjusted EBITDA loss from continuing operations. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company’s ongoing operating results and trends.

Management is excluding from some or all of its non-IFRS results (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax (credit)/expense, (5) amortization of deferred expenses, (6) equity-settled share-based payment expenses, (7) acquisition and transaction-related costs, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss on warrant liabilities, (12) share of loss of equity-accounted investees, net of tax, and (13) loss from discontinued operation, net of tax — items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company’s public disclosures.

In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company’s non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned “Reconciliation of loss for the period under IFRS and adjusted EBITDA loss (Non-IFRS)”, “Revenue by business unit from continuing operations (Non-IFRS)” and “Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)” set forth at the end of this document.

Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)

—————————————————————————

^[6] Includes equity-settled share-based payment expenses from continuing operations as follows:

^[7] ACT Genomics Holdings Company Limited (“ACT Genomics”) are classified as discontinued operations in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations (“IFRS 5”). In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income.